A preclinical platform for assessing antitumor effects and systemic toxicities of cancer drug targets

The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer

(2021) Stephin J. Vervoort et al.   CELL

Prospective analysis of myocardial strain through the evolution of Chagas disease in the hamster animal model

(2021) Fernando Fonseca França Ribeiro et al.   INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING

Somatic tissue engineering in mouse models reveals an actionable role for WNT pathway alterations in prostate cancer metastasis

(2020) Josef Leibold et al.   Cancer Discovery

Targeted protein degradation as a powerful research tool in basic biology and drug target discovery

(2020) Tao Wu et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Improving CRISPR Genome Editing by Engineering Guide RNAs

(2019) Su Bin Moon et al.   TRENDS IN BIOTECHNOLOGY

AZD4573 is a highly selective CDK9 inhibitor that suppresses Mcl-1 and induces apoptosis in hematological cancer cells.

(2019) Justin Cidado et al.   CLINICAL CANCER RESEARCH

A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies

(2019) Darren C. Phillips et al.   LEUKEMIA

Cdk9 as an Appealing Target for Therapeutic Interventions

(2018) Shirin Eyvazi et al.   CURRENT DRUG TARGETS

The emerging picture of CDK9/P-TEFb: more than 20 years of advances since PITALRE

(2017) Nikolas Ferreira dos Santos Paparidis et al.   Molecular BioSystems

Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation

(2017) Calla M Olson et al.   Nature Chemical Biology

A phase 1 clinical trial of flavopiridol consolidation in chronic lymphocytic leukemia patients following chemoimmunotherapy

(2016) Farrukh T. Awan et al.   ANNALS OF HEMATOLOGY

Overview of CDK9 as a target in cancer research

(2016) Fatima Morales et al.   CELL CYCLE

Inhibition of CDK9 as a therapeutic strategy for inflammatory arthritis

(2016) Annelie Hellvard et al.   Scientific Reports

Genetic and pharmacological inhibition of CDK9 drives neutrophil apoptosis to resolve inflammation in zebrafish in vivo

(2016) Laura J. Hoodless et al.   Scientific Reports

Preclinical Mouse Cancer Models: A Maze of Opportunities and Challenges

(2015) Chi-Ping Day et al.   CELL

A Phase II, Single-Arm, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of P276-00, a Cyclin-Dependent Kinase Inhibitor, in Patients With Relapsed or Refractory Mantle Cell Lymphoma

(2015) Ryan D. Cassaday et al.   Clinical Lymphoma Myeloma & Leukemia

Final results of EFC6663: A multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia

(2015) Mark C. Lanasa et al.   LEUKEMIA RESEARCH

Compensatory induction of MYC expression by sustained CDK9 inhibition via a BRD4-dependent mechanism

(2015) Huasong Lu et al.   eLife

HTSeq--a Python framework to work with high-throughput sequencing data

(2014) S. Anders et al.   BIOINFORMATICS

Trimmomatic: a flexible trimmer for Illumina sequence data

(2014) Anthony M. Bolger et al.   BIOINFORMATICS

p53-Dependent Nestin Regulation Links Tumor Suppression to Cellular Plasticity in Liver Cancer

(2014) Darjus F. Tschaharganeh et al.   CELL

CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma

(2014) Chun-Hao Huang et al.   GENES & DEVELOPMENT

Pancreatic Cancer Induced by In Vivo Electroporation-Enhanced Sleeping Beauty Transposon Gene Delivery System in Mouse

(2014) June-Shine Park et al.   PANCREAS

Conditional Reverse Tet-Transactivator Mouse Strains for the Efficient Induction of TRE-Regulated Transgenes in Mice

(2014) Lukas E. Dow et al.   PLoS One

Inducible In Vivo Silencing of Brd4 Identifies Potential Toxicities of Sustained BET Protein Inhibition

(2014) Jessica E. Bolden et al.   Cell Reports

Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non-Hodgkin's lymphoma

(2013) Jeffrey A. Jones et al.   AMERICAN JOURNAL OF HEMATOLOGY

A phase I trial of flavopiridol in relapsed multiple myeloma

(2013) Craig C. Hofmeister et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

DNA targeting specificity of RNA-guided Cas9 nucleases

(2013) Patrick D Hsu et al.   NATURE BIOTECHNOLOGY

An Optimized microRNA Backbone for Effective Single-Copy RNAi

(2013) Christof Fellmann et al.   Cell Reports

STAR: ultrafast universal RNA-seq aligner

(2012) Alexander Dobin et al.   BIOINFORMATICS

Perspective of Cyclin-dependent kinase 9 (CDK9) as a Drug Target

(2012) Vladimir Krystof et al.   CURRENT PHARMACEUTICAL DESIGN

Conditional Disruption of Axin1 Leads to Development of Liver Tumors in Mice

(2012) Gui Jie Feng et al.   GASTROENTEROLOGY

Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia

(2012) J. E. Karp et al.   HAEMATOLOGICA

Cyclin-Dependent Kinase 9 Activity Regulates Neutrophil Spontaneous Apoptosis

(2012) Keqing Wang et al.   PLoS One

A Rapid and Scalable System for Studying Gene Function in Mice Using Conditional RNA Interference

(2011) Prem K. Premsrirut et al.   CELL

Reversible suppression of an essential gene in adult mice using transgenic RNA interference

(2011) K. McJunkin et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies

(2010) Christophe Le Tourneau et al.   EUROPEAN JOURNAL OF CANCER

How to improve R&D productivity: the pharmaceutical industry's grand challenge

(2010) Steven M. Paul et al.   NATURE REVIEWS DRUG DISCOVERY